A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
Crossref DOI link: https://doi.org/10.1186/S13045-016-0266-1
Published Online: 2016-04-12
Published Print: 2016-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Pellegrini, Cinzia
,
Dodero, Anna
Chiappella, Annalisa
Monaco, Federico
Degl’Innocenti, Debora
Salvi, Flavia
Vitolo, Umberto
Argnani, Lisa
Corradini, Paolo
Zinzani, Pier Luigi